↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
KKR's Integer deal at **4.7x leverage** signals selective LBO debt reopening—healthcare's non-discretionary revenue now commands financing denied to consumer.
$5.89 billion
acquisition of Integer Holdings on August 29
$1 billion
in a sector that absorbed
41%
of global PE capital deployed despite August volumes falling
$197.26
per share
KKR closed its $5.89 billion acquisition of Integer Holdings on August 29, the largest healthcare private equity transaction of the month and one of four deals above $1 billion in a sector that absorbed 41% of global PE capital deployed despite August volumes falling 22% sequentially. Integer, a contract manufacturer of cardiac rhythm management devices and neuromodulation systems, exits public markets at $197.26 per share, a 28% premium to its 90-day VWAP before announcement.
The transaction marks KKR's third medical device platform acquisition since 2021, following its $13 billion Labcorp diagnostics carveout and $3.4 billion purchase of PRA Health Sciences assets. Integer generated $1.48 billion in trailing revenue with 18.2% EBITDA margins, serving eight of the top ten cardiovascular device OEMs under multi-year supply agreements. The company operates fourteen manufacturing sites across six countries, with 64% of revenue tied to implantable cardiac devices where ASP erosion has slowed to 1.8% annually from 4.1% in 2019-2021. KKR financed the take-private with $2.1 billion in equity, $3.2 billion in leveraged loan commitments priced at SOFR plus 375 basis points, and Integer's existing $580 million cash balance—a debt-to-EBITDA multiple of 4.7x that signals reopened appetite for healthcare LBOs after eighteen months of constrained broadly syndicated loan markets.
The timing reflects structural re-pricing in medical technology. Integer's public valuation had compressed to 11.2x forward EBITDA by June 2024, down from 14.8x in early 2022, despite the company maintaining 96% customer retention and winning $340 million in new program awards over the prior twelve months. Private equity now sees arbitrage: take margin-stable contract manufacturers private at trough multiples, consolidate fragmented capacity, then sell integrated platforms to strategic buyers or re-IPO at 14-16x once rate clarity returns. Three comparable medtech contract manufacturers—TE Connectivity's medical unit, Flex Ltd.'s health solutions division, and privately-held Heraeus Medical Components—trade or last transacted at 13.1x to 15.7x EBITDA, suggesting KKR paid a 15-22% discount to normalized valuation despite the public premium.
Healthcare absorbed $47 billion of the $114 billion in global PE capital deployed in August, the highest sector concentration since March 2021. Four other transactions closed above $1 billion: Permira's $2.3 billion acquisition of Medline's renal care business, Carlyle's $1.8 billion purchase of Agiliti's surgical equipment portfolio, Bain Capital's $1.4 billion take-private of Tivity Health, and CD&R's $1.1 billion buy of R1 RCM's physician revenue cycle assets. The pattern is consistent—each deal targeted non-discretionary healthcare infrastructure with 90%+ revenue visibility, sub-2% annual volume variance, and 12-18% unlevered IRR potential at entry multiples between 10.8x and 12.4x EBITDA. Debt markets accommodated these structures while turning away three consumer discretionary LBOs and two industrial buyouts that sought similar leverage ratios, a reversal from 2021 when consumer deals commanded 50-75 basis point pricing advantages.
Allocators should monitor three follow-on events. First, KKR will likely pursue tuck-in acquisitions of smaller cardiac and neuro component suppliers within six to nine months—at least two targets with $150-400 million in revenue are already in exploratory discussions according to supply chain intelligence. Second, Integer's two largest public competitors, Greatbatch and Symmetry Surgical, now face take-private pressure as activist funds build positions expecting similar premium bids by Q1 2025. Third, the leveraged loan syndication for Integer will price in mid-September; if oversubscribed, expect $8-12 billion in additional healthcare LBO announcements before year-end as sponsors test whether August's debt reception was anomaly or inflection.
By October, the market will know whether healthcare became private equity's all-weather sector or simply the last one left with lenders willing to clear.
Branded by POPS4 · proof in 60 seconds
For the principal
Healthcare buyouts now clearing at leverage levels unavailable elsewhere—consider rotating growth capital toward non-discretionary medical infrastructure before multiples re-rate 12-18 months forward.
For the operator
Monitor Integer's tuck-in M&A within six months—KKR's playbook suggests $600M-1.2B in add-ons before exit, creating supplier consolidation pressure and potential distressed opportunities among subscale component makers.
For the house
Initiate coverage on Greatbatch and Symmetry Surgical for event-driven pairs trade—activist positioning suggests 22-30% take-private premiums possible by Q1 2025 if Integer debt syndicates successfully.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.